Evidence map›Paper›PMID 40944447›Full record

ArticleProtein science : a publication of the Protein Society2025

Genetic code expansion and enzymatic modifications as accessible methods for studying site-specific post-translational modifications of alpha-synuclein and tau.

Ibrahim G Saleh, Marie Shimogawa, Jennifer Ramirez, Bernard Abakah, Yarra Venkatesh, Honey Priya James, Ming-Hao Li, Sarah A Louie, Marshall G Lougee, Wai-Kit Chia and 8 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ibrahim G SalehDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0003-3263-7671
Marie ShimogawaDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jennifer RamirezGraduate Group in Biochemistry, Biophysics, and Chemical Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bernard AbakahDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yarra VenkateshDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Honey Priya JamesDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ming-Hao LiDepartment of Biochemistry, Weill Cornell Medicine, New York, New York, USA.
Sarah A LouieDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA.
Marshall G LougeeDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Wai-Kit ChiaDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Christopher BrueDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Richard B CooleyDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA.
Ryan A MehlDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA.
Tobias BaumgartDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert H MachDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David EliezerDepartment of Biochemistry, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-1311-7537
Elizabeth RhoadesDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
E James PeterssonDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-3854-9210

Funding

Medicinal Chemistry CoreU19NS110456 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ROBERT H MACH · 2019 to 2026
$44.1M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2019 to 2023
$18.1M
Training in Alzheimer’s and Age-Related Neurodegenerative DiseasesT32AG000255 · NIA · UNIVERSITY OF PENNSYLVANIA · PI ALICE S CHEN-PLOTKIN, VIRGINIA M LEE · 1997 to 2026
$12.5M
The GCE4All Center: Unleashing the Potential of Genetic Code Expansion for Biomedical ResearchRM1GM144227 · NIGMS · OREGON STATE UNIVERSITY · PI RYAN A MEHL · 2022 to 2026
$6.2M
Structure and Function of Protein Disorder in Membrane Trafficking and OrganizationR35GM136686 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELIEZER, DAVID · 2020 to 2025
$4.5M
Membrane shape transition control in cellular membrane trafficking phenomenaR01GM097552 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BAUMGART, TOBIAS · 2011 to 2023
$4.5M
Equipment supplement: Defining Roles Of NitroTyrosine In Disease Via Genetic Code ExpansionR01GM114653 · NIGMS · OREGON STATE UNIVERSITY · PI MEHL, RYAN A · 2015 to 2024
$2.6M
Predoctoral Training at the Chemistry-Biology InterfaceT32GM133398 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ronen Marmorstein, Ernest James Petersson · 2020 to 2026
$2.4M
Studying Aggregation in Neurodegenerative Disease Using Synthetic ProteinsR01NS103873 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Ernest James Petersson · 2019 to 2026
$2.1M
Studying Aggregation in Neurodegenerative Disease using Synthetic ProteinsRF1NS103873 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES · 2023 to 2023
$1.8M
Combinatorial effects of PTMs on a-Synuclein structure, function and aggregationRF1NS125770 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES, RHOADES, ELIZABETH · 2022 to 2022
$1.7M
Bruker RapifleX MALDI TOF/TOF Mass SpectrometerS10OD030460 · OD · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES · 2021 to 2021
$881k
Nakajima FoundationNIA NIH HHS T32 AG000255NIA NIH HHS U19 AG062418NIGMS NIH HHS R01 GM097552NIGMS NIH HHS R01 GM114653NIGMS NIH HHS R35 GM136686NIGMS NIH HHS RM1 GM144227NIGMS NIH HHS T32 GM133398NIH HHS R01-GM097552NIH HHS RF1-NS103873NIH HHS RF-1NS125770NIH HHS RM1-GM144227NIH HHS S10 OD030460NIH HHS S10-OD030460NIH HHS T32-AG000255NIH HHS T32-GM133398NIH HHS U19-NS110456NINDS NIH HHS R01 NS103873NINDS NIH HHS R01 NS125770NINDS NIH HHS RF1 NS103873NINDS NIH HHS RF1 NS125770NINDS NIH HHS U19 NS110456NSF CHE-1827457
6 · The paper itself

Abstract

Alpha-synuclein (αS) and tau play important roles in the pathology of Parkinson's disease and Alzheimer's disease, respectively, as well as numerous other neurodegenerative diseases. Both proteins are classified as intrinsically disordered proteins (IDPs), as they have no stable structure that underlies their function in healthy tissue, and both proteins are prone to aggregation in disease states. There is substantial interest in understanding the roles that post-translational modifications (PTMs) play in regulating the structural dynamics and function of αS and tau monomers, as well as their propensity to aggregate. While there have been many valuable insights into site-specific effects of PTMs garnered through chemical synthesis and semi-synthesis, these techniques are often outside of the expertise of biochemistry and biophysics laboratories wishing to study αS and tau. Therefore, we have assembled a primer on genetic code expansion and enzymatic modification approaches to installing PTMs into αS and tau site-specifically, including isotopic labeling for NMR and fluorescent labeling for biophysics and microscopy experiments. These methods should be enabling for those wishing to study authentic PTMs in αS or tau as well as the broader field of IDPs and aggregating proteins.

Indexed as

alpha-SynucleinGenetic CodeProtein Processing, Post-Translationaltau ProteinsHumansIsotope Labelingalpha-Synucleintau Proteinsalpha‐synucleingenetic code expansionpost‐translational modificationtau

Identifiers

PMID40944447
PMCPMC12432407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.